Our investment approach is primarily focused around therapeutics. We look for novel drugs and modalities in a wide variety of disease areas, and invest across the spectrum of drug development. We are equally comfortable in company formation as we are in participating in syndicates with co-investors.
Our process is heavily reliant on proprietary deal flow. With a rich history of working with hundreds of biotech companies and entrepreneurial teams in past lives, our team is particularly well networked globally to identify and evaluate novel, exciting breakthroughs.
Once invested, we work in close partnership with management teams to execute R&D plans efficiently. Whilst the world of academic medical research is more inter-connected and collaborative than ever, we believe capital markets supporting the industry are not all equally well served around the world. This provides geographical and tactical opportunities for attractive investments that meet both commercial and scientific aims to make a meaningful contribution to all stakeholders – from patients to scientists to investors.